NTLA
Intellia Therapeutics Inc.
$17.26
+$1.67(+10.71%)
58
Overall
--
Value
58
Tech
--
Quality
Market Cap
$1.67B
Volume
8.88M
52W Range
$5.90 - $21.94
Target Price
$32.78
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||||
| Total Revenue | $16.5M | $26.1M | $30.4M | $43.1M | $58.0M | $33.1M | $52.1M | $36.3M | $57.9M | ||
| Total Revenue | $16.5M | $26.1M | $30.4M | $43.1M | $58.0M | $33.1M | $52.1M | $36.3M | $57.9M | ||
| COST OF GOODS SOLD | |||||||||||
| Cost of Revenue | $-48.6M | $-95.7M | $-121.3M | $149.5M | $-194.6M | -- | -- | -- | -- | ||
| GROSS PROFIT | |||||||||||
| Gross Profit | $16.5M | $26.1M | $30.4M | $43.1M | $58.0M | $33.1M | $52.1M | $36.3M | $57.9M | ||
| OPERATING EXPENSES | |||||||||||
| Operating Expenses | $48.6M | $95.7M | $121.3M | $149.5M | $194.6M | $300.9M | $510.3M | $551.6M | $592.1M | ||
| Research & Development | $31.8M | $67.6M | $89.1M | $108.4M | $150.4M | $229.8M | $420.0M | $435.1M | $466.3M | ||
| Research Expense | $31.8M | $67.6M | $89.1M | $108.4M | $150.4M | $229.8M | $420.0M | $435.1M | $466.3M | ||
| Selling, General & Administrative | $16.8M | $28.0M | $32.2M | $41.1M | $44.2M | $71.1M | $90.3M | $116.5M | $125.8M | ||
| General & Administrative Expenses | $16.8M | $28.0M | $32.2M | $41.1M | $44.2M | $71.1M | $90.3M | $116.5M | $125.8M | ||
| Salaries & Wages | $-6.7M | $-15.3M | $-17.0M | $-15.1M | $-19.9M | -- | -- | $134.1M | $154.3M | ||
| Depreciation & Amortization | $-1.1M | $-3.0M | $-4.5M | $5.6M | $6.3M | $6.9M | $7.6M | $9.0M | $10.3M | ||
| Depreciation & Amortization | $-1.1M | $-3.0M | $-4.5M | $5.6M | $6.3M | $6.9M | $7.6M | $9.0M | $10.3M | ||
| Other Operating Expenses | -- | -- | -- | $9.7M | $11.4M | $16.2M | $22.5M | $33.4M | $37.5M | ||
| OPERATING INCOME | |||||||||||
| Operating income | $-32.2M | $-69.6M | $-90.9M | $-106.4M | $-136.6M | $-267.9M | $-458.2M | $-515.3M | $-534.3M | ||
| EBITDA | $-30.5M | $-64.5M | $-81.5M | $-97.4M | $-130.3M | $-261.0M | $-462.6M | $-472.2M | $-508.7M | ||
| NON-OPERATING ITEMS | |||||||||||
| Intinc | $525.0K | $2.0M | $5.5M | $6.8M | $2.4M | $1.3M | $8.5M | $49.8M | $47.8M | ||
| Net Non-Operating Interest Income/Expense | $525.0K | $2.0M | $5.5M | $6.8M | $2.4M | $1.3M | $8.5M | $49.8M | $47.8M | ||
| Gain on Sale of Securities | -- | -- | $-28.0K | $289.0K | $-260.0K | -- | -- | -- | $-32.6M | ||
| Other Income/Expense | -- | -- | $28.0K | $-289.0K | $-11.6M | $3.5M | $-24.6M | $10.5M | $31.8M | ||
| Other Special Charges | -- | -- | $22.9M | $27.1M | $11.6M | $22.5M | $52.1M | $23.5M | $22.1M | ||
| PRE-TAX INCOME | |||||||||||
| EBIT | $-31.6M | $-67.5M | $-85.4M | $-99.2M | $-136.6M | $-267.9M | $-474.2M | $-481.2M | $-519.0M | ||
| Pre-Tax Income | $-31.6M | $-67.5M | $-85.4M | $-99.2M | $-134.2M | $-270.0M | $-474.2M | $-476.0M | $-519.0M | ||
| NET INCOME | |||||||||||
| Net Income | $-31.6M | $-67.5M | $-85.4M | $-99.5M | $-134.2M | $-267.9M | $-474.2M | $-481.2M | $-519.0M | ||
| Net Income (Continuing Operations) | $-31.6M | $-67.5M | $-85.4M | $-99.5M | $-134.2M | $-267.9M | $-474.2M | $-481.2M | $-519.0M | ||
| Net Income (Discontinued Operations) | $-31.6M | $-67.5M | $-85.4M | $-99.5M | $-134.2M | $-267.9M | $-474.2M | $-481.2M | $-519.0M | ||
| Net Income (Common Stockholders) | $-31.6M | $-67.5M | $-85.4M | $-99.2M | $-134.2M | $-267.9M | $-475.8M | $-481.2M | $-519.0M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | $-513.1M | ||
| TOTALS | |||||||||||
| Total Expenses | -- | -- | -- | $298.9M | -- | $300.9M | $510.3M | $551.6M | $592.1M | ||
| SHARE & EPS DATA | |||||||||||
| Average Shares Outstanding | $22.2M | $36.0M | $43.1M | $47.2M | $56.0M | $70.9K | $77.0M | $88.8M | $98.8M | ||
| Average Shares Outstanding (Diluted) | $22.3M | $35.9M | $43.1M | $47.2M | $56.0M | $70.9K | $77.0M | $88.8M | $98.8M | ||
| Shares Outstanding | $36.0M | $42.4M | $45.2M | $50.5M | $67.7M | $74.7M | $88.0M | $96.1M | $103.5M | ||
| Basic EPS | -- | -- | -- | -- | -- | -- | $-6.16 | $-5.42 | $-5.25 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-6.16 | $-5.42 | $-5.25 | ||
| Diluted EPS | $-1.42 | $-1.88 | $-1.98 | $-2.11 | $-2.4 | $-3.78 | $-6.16 | $-5.42 | $-5.25 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-1.98 | $-2.11 | $-2.4 | $-3.78 | $-6.16 | $-5.42 | $-5.25 | ||
| OTHER METRICS | |||||||||||
| Earnings from equity interest | -- | -- | -- | -- | -- | $-1.3M | $-11.1M | $-15.6M | -- | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | -- | -- | -- | $-1.3M | $-11.1M | $-15.6M | -- | ||
| Gain On Sale Of Business | -- | -- | -- | -- | -- | -- | -- | $1.6M | -- | ||
| Other Gand A | $16.8M | $28.0M | $32.2M | $41.1M | $44.2M | $71.1M | $90.3M | $116.5M | $125.8M | ||
| Rent And Landing Fees | $16.8M | $28.0M | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NTLA | $17.26 | +10.7% | 8.88M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Intellia Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW